New sales milestone payments in Europe in connection with the new Licensing Agreement with ProStrakan

New sales milestone payments in Europe in connection with the new Licensing
Agreement with ProStrakan

This is a complement to the press release from yesterday. In connection with the
new agreement with ProStrakan, apart from higher royalty rates, the potential
sales milestone payments in Europe have increased from 10.0 MEUR to 29.9 MEUR.

For more information, please contact:
Claes Wenthzel, Executive Vice President & CFO, Orexo AB
Tel: +46 (0)708-62 01 22
E-mail: claes.wenthzel@orexo.com

TO THE EDITORS
About Orexo

Orexo is a pharmaceutical company, focusing on development of new, patented
drugs by combining well-documented substances with innovative technologies, and
the development of new treatments for respiratory and inflammatory diseases.

Orexo has a broad and competitive late-stage product portfolio, including two
marketed products, five products in clinical phase and two in registration
stage.
To date, Orexo have out-licensed the market rights for Abstral®/Rapinyl™ for the
US, the EU and Japan markets and the world-wide market rights for Sublinox
(OX22) and OX-NLA, and a out-license and research collaboration with Boehringer
Ingelheim regarding the development of a new class of drugs to treat pain and
inflammation. Abstral®/Rapinyl™ was approved in Europe on June 24, 2008. Orexo
has established a Nordic sales force by entering into a joint venture with
ProStrakan.  Abstral® will be launched in Sweden during Q3 this year.

Orexo has its head office in Uppsala, Sweden and is listed on the OMX Nordic
Exchange Stockholm, Small Cap (ticker: ORX).

www.orexo.com


About ProStrakanProStrakan Group plc is a rapidly growing international specialty pharmaceutical
company engaged in the development and commercialisation of prescription
medicines for the treatment of unmet therapeutic needs in major markets. 

ProStrakan's head office and development facilities are situated in Galashiels
in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products
are handled by commercial subsidiaries in the UK, France, Germany, Spain and
other EU countries. ProStrakan has recently commenced the expansion its
operations into the US.
www.prostrakan.com